Treats acute lymphoblastic leukemia (ALL). ANDA 216453, held by Elite Laboratories. Methotrexate Sodium.
As of Nov 21, 2026, ANDA 216453 (Methotrexate Sodium), held by Elite Laboratories, was first approved by FDA on May 16, 2024, with 1 approved supplement and 0 published complete response letters.
Methotrexate Tablets are a diydrofolate reductase inhibitor indicated for the:
| Date | Submission | Status | Documents |
|---|---|---|---|
| May 16, 2024 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Methotrexate SodiumEQ 2.5MG BASE · tablet;oral | Methotrexate Sodium | Rx |
| May 27, 2026 | Supplement 3Labeling · Standard review | Approved | None posted |
| May 16, 2024 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters